NEW YORK (GenomeWeb) – Australian firm Genome.One and US-based OneOme said today that they have partnered to provide a joint service in Australia to analyze individuals' genetic disease risks and pharmacogenomic-related variants.
As part of the service launched earlier this month, customers will receive genome sequencing provided by Genome.One and pharmacogenomic testing using OneOme's RightMed test.